Malignant Pleural Mesothelioma

P=N/A, N=30, Active, not recruiting, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Nov 2026

P1, N=260, Recruiting, IDEAYA Biosciences | Not yet recruiting --> Recruiting

P2, N=41, Active, not recruiting, Istituto Oncologico Veneto IRCCS | Recruiting --> Active, not recruiting

Single biomarkers like miRNAs, mesothelin, and VOCs show promise, but further validation is needed in larger cohorts with correct control groups. A multi-omics approach, which integrates biomarker panels from various -omics areas, has the potential to enhance diagnostic accuracy.

The prominent conformation modifications of each complex during MD simulation has been determined via Markov state model confirms the stability of PLU-IPA in the binding site. These findings underscore the intricate molecular mechanisms underlying PM and highlight PLU-IPA as a potential therapeutic target for future investigations.

These include combination regimens with chemotherapy, radiotherapy, surgery, epigenetic modulators, anti-angiogenic agents, and novel immunotherapies such as next-generation checkpoint inhibitors (LAG-3, VISTA), immune-suppressive cell-targeting agents, vaccines, cell-based therapies, and oncolytic viruses. Collectively, these advancements underscore the importance of integrating histological classification with molecular and microenvironmental profiling to refine patient selection and guide the development of combination strategies aimed at transforming "cold" mesotheliomas into "hot," immune-responsive tumors, thereby enhancing the efficacy of ICB.

P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Nov 2024 --> Dec 2026

In xenograft models, CAR-T cells significantly prolonged median survival. Thus, UCB-derived anti-MSLN CAR-Ts showed reduced exhaustion, increased memory T cell proportions, and enhanced anti-tumor efficacy in vitro and in vivo.

Targeted agents did not demonstrate a significant clinical benefit in mesothelioma treatment, nevertheless a small group of patients might harbor potentially actionable somatic mutations, as in homologous repair recombination genes. In this paper we report two cases of patients with heavily pretreated pleural mesothelioma that had a relevant clinical benefit with rucaparib treatment based on somatic BRCA 1 and BRCA 2 mutations detected through next generation sequencing.

P=N/A, N=240, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Oct 2025 --> Oct 2030 | Trial primary completion date: Jan 2024 --> Jan 2030

P1, N=260, Not yet recruiting, IDEAYA Biosciences

P1, N=20, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2025 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Feb 2027